Sangui BioTech International Inc. / Key word(s): Regulatory Approval
06.11.2014 / 12:00
Sangui BioTech International officially approved as trading on OTCQB
Witten, Germany, November 6, 2014 - OTC Markets Group has officially informed Sangui Biotech International, Inc., that the application of the company for continued trading on the OTCQB venture market place for early stage and developing companies was approved of today. Subsequent to the reorganization of the OTC markets, resulting in higher transparency levels and significantly improved services for issuers and investors in particular on OTCQB, Sangui has submitted all the mandatory documents and successfully met all of the initial requirements.
Sangui BioTech henceforth trades on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB:SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Investors can find real-time quotes and market information for the company on www.otcmarkets.com.
Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.
For more information please contact:
Joachim Fleing
Phone: +49 (179) 7963472
Fax: +49 (2302) 915191
e-mail: fleing@sangui.de